Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

According to the recently published report 'Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update'; Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) pipeline Target constitutes close to 37 molecules.

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Non-receptor tyrosine-protein kinase TYK2 is an enzyme encoded by the TYK2 gene. It is involved in intracellular signal transduction by involving in the initiation of type I IFN signaling. It phosphorylates the interferon-alpha/beta receptor alpha chain. It plays an import role in inflammation.

The report outlays comprehensive information on the Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 6, 9, 2, 12 and 6 respectively. Report covers products from therapy areas Immunology, Gastrointestinal, Dermatology, Musculoskeletal Disorders, Oncology, Central Nervous System, Infectious Disease, Respiratory, Metabolic Disorders, Ophthalmology and Undisclosed which include indications Autoimmune Disorders, Psoriasis, Systemic Lupus Erythematosus, Plaque Psoriasis (Psoriasis Vulgaris), Inflammatory Bowel Disease, Rheumatoid Arthritis, Atopic Dermatitis (Atopic Eczema), Psoriatic Arthritis, Ulcerative Colitis, Inflammation, Unspecified Immunological Disorders, Asthma, Colorectal Cancer, Coronavirus Disease 2019 (COVID-19), Crohn's Disease (Regional Enteritis), Dermatomyositis, Multiple Sclerosis, T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), Alopecia Areata, Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Ankylosing Spondylitis (Bekhterev's Disease), Arthritis, B-Cell Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE), Chronic Obstructive Pulmonary Disease (COPD), Chronic Urticaria Or Hives, Colon Cancer, Cutaneous T-Cell Lymphoma, Diabetic Macular Edema, Diffuse Large B-Cell Lymphoma, Enteritis, Fibrosis, Follicular Lymphoma, Hidradenitis Suppurativa, Intermediate Uveitis, Kidney Cancer (Renal Cell Cancer), Lupus Erythematosus, Lymphoma, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Melanoma, Neuroinflammation, Non-infectious Uveitis, Pancreatic Cancer, Panuveitis, Peripheral T-Cell Lymphomas (PTCL), Posterior Uveitis, Skin Cancer, Solid Tumor, Subacute Cutaneous Lupus Erythematosus (SCLE), Unspecified, Unspecified B-Cell Lymphomas, Unspecified Dermatological Disorders, Vitiligo and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The report provides a snapshot of the global therapeutic landscape for Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)
• The report reviews Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
• The report assesses Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope